Brendan M. Weiss
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)

Dr. Brendan M. Weiss

Hematology Oncology
3400 Civic Center Blvd, 2nd Floor, 
Philadelphia, PA 
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
3400 Civic Center Blvd, 2nd Floor, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Brendan Weiss is a Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Weiss is rated as a Distinguished provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). His top areas of expertise are Primary Amyloidosis, Multiple Myeloma, Smoldering Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 72 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 8 articles in the study of Monoclonal Gammopathy of Undetermined Significance (MGUS).

Specialties
Hematology Oncology
Licenses
Internal Medicine in PA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

3400 Civic Center Blvd, 2nd Floor, Philadelphia, PA 19104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Other, Drug
Study Phase: Phase 3
A Prospective Study Of Circulating Multiple Myeloma Cells As A Biomarker Of Progression In Myeloma Precursor States (MGUS And SMM)
A Prospective Study Of Circulating Multiple Myeloma Cells As A Biomarker Of Progression In Myeloma Precursor States (MGUS And SMM)
Enrollment Status: Completed
Publish Date: May 20, 2022
Prospective Observation of Cardiac Safety With Proteasome Inhibition
Prospective Observation of Cardiac Safety With Proteasome Inhibition
Enrollment Status: Completed
Publish Date: September 14, 2020
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
Enrollment Status: Completed
Publish Date: April 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)
Enrollment Status: Terminated
Publish Date: March 26, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

71 Total Publications

Strategies for successful dose optimization in oncology drug development: a practical guide.
Strategies for successful dose optimization in oncology drug development: a practical guide.
Journal: Journal of biopharmaceutical statistics
Published: August 11, 2024
Similar Doctors
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Subhash C. Proothi
Hematology Oncology | Hematology | Oncology
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Subhash C. Proothi
Hematology Oncology | Hematology | Oncology

St Lukes Physician Group Inc

1872 St Lukes Blvd, Fl 1, 
Easton, PA 
 (48.7 miles away)
484-526-7575
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Subhash Proothi is a Hematologist Oncology specialist and a Hematologist in Easton, Pennsylvania. Dr. Proothi is rated as a Distinguished provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). His top areas of expertise are Adult Immune Thrombocytopenia, Thrombocytopenia, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Hemangioma Thrombocytopenia Syndrome.

Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Andres Ferber
Hematology Oncology | Hematology | Oncology
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Andres Ferber
Hematology Oncology | Hematology | Oncology

Aria Health Physician Services

10800 Knights Rd, 
Philadelphia, PA 
 (14.0 miles away)
215-890-3030
Languages Spoken:
English, French, Portuguese, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Andres Ferber is a Hematologist Oncology specialist and a Hematologist in Philadelphia, Pennsylvania. Dr. Ferber is rated as a Distinguished provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Familial Mixed Cryoglobulinemia, Cryoglobulinemia, and Chronic Lymphocytic Leukemia (CLL). Dr. Ferber is currently accepting new patients.

Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Andrew L. Himelstein
Hematology Oncology | Palliative Medicine | Hematology
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Andrew L. Himelstein
Hematology Oncology | Palliative Medicine | Hematology

Medical Oncology Hematology Consultants PA

4701 Ogletown Stanton Rd, Suite 3400, 
Newark, DE 
 (31.2 miles away)
302-366-1200
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Andrew Himelstein is a Hematologist Oncology specialist and a Palliative Medicine provider in Newark, Delaware. Dr. Himelstein is rated as a Distinguished provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). His top areas of expertise are Inflammatory Breast Cancer, Paget Disease of the Breast, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Familial Prostate Cancer. Dr. Himelstein is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Weiss's expertise for a condition
ConditionClose
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile